Trial Profile
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 06 Jan 2022 Status changed from recruiting to completed.
- 08 Jun 2018 Planned number of patients changed from 1767 to 1770.
- 11 Apr 2018 Planned number of patients changed from 1699 to 1767.